GlassScriptPhysician profile
John P Moschello
NPI 1073592978
$8,732.55
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $2,117 · 2021: $2,051 · 2022: $1,108 · 2023: $1,447 · 2024: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,075.48 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $1,018.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $858.02 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $706.61 | 2021-2023 | |
| Pfizer INC. | $536.03 | 2019-2024 | |
| Abbvie INC. | $519.66 | 2019-2024 | |
| Amgen INC. | $508.77 | 2019-2023 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $505.85 | 2019-2023 | Trintellix |
| Lilly USA, LLC | $419.57 | 2020-2023 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $381.15 | 2019-2021 | |
| Glaxosmithkline, LLC. | $379.76 | 2019-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.23 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $346.69 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $238.85 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Eisai INC. | $169.75 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $108.91 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $106.48 | 2019-2020 | |
| Astellas Pharma US INC | $85.94 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.82 | 2020-2021 | |
| Genentech USA, INC. | $58.99 | 2019-2021 | |
| Medtronic, INC. | $50.47 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.28 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $35.56 | 2021-2022 | |
| Esperion Therapeutics, INC. | $26.10 | 2020 | |
| Almatica Pharma LLC | $21.32 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Exact Sciences Corporation | $21.26 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $21.01 | 2023 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $17.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.44 | 2019 | |
| Radius Health, INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moschello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.